Invex Therapeutics Ltd (ASX:IXC)

68.0¢

right-arrow Created with Sketch. 0.05 (7.94%)
MCAP $51.10M
Last trade 16.10pm 26/11/2021 20mins delayed

Latest Announcements

25/11/2021IXCInvex Therapeutics Ltd
1,027
MCap
25/11/2021IXCInvex Therapeutics Ltd
23/11/2021IXCInvex Therapeutics Ltd
10/11/2021IXCInvex Therapeutics Ltd
04/11/2021IXCInvex Therapeutics Ltd
04/11/2021 Price SensitivePSIXCInvex Therapeutics Ltd
25/10/2021IXCInvex Therapeutics Ltd
20/10/2021 Price SensitivePSIXCInvex Therapeutics Ltd

Company Overview

Invex Therapeutics Ltd is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialisation of Presendin (Exenatide) for neurological conditions relating to raised intracranial pressure. The Company received written responses from the United States Food and Drug Administration (FDA) Division of Neurology relating to its proposed Phase III clinical trial design for Presendin in Idiopathic Intracranial Hypertension (IIH). Exenatide is a glucagon-like peptide-1 receptor agonist approved for the treatment of type II diabetes. The Company focuses on reformulating Exenatide to deliver it in a way that enables exploitation of its unknown ability to reduce cerebral spinal fluid secretion in the choroid plexus of the brain. The Company intends to progress expediently to clinical evaluation and undertake the registration of different formulations of Exenatide optimized to treat different neurological conditions.

IXC in the news

Invex Therapeutics (IXC) is set to launch a phase three clinical trial…
Invex Therapeutics (IXC) signs an agreement for the commercialisation of its treatment…
Invex Therapeutics (IXC) is reviewing its upcoming Presendin hypertension treatment trial after…
The European Medical Agency (EMA) has advised a single study on the…

Search Previous Announcements